Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.73 0.0%	$17.87	$13.40 ▼ $25.23	$3.64B	0.65	1.94 million shs	373,259 shs
ACLX Arcellx	$66.34 -0.3%	$61.76	$47.86 ▼ $107.37	$3.65B	0.28	603,913 shs	144,521 shs
MRUS Merus	$55.18 -0.4%	$46.03	$33.19 ▼ $62.98	$3.82B	1.04	748,892 shs	289,279 shs
SNDX Syndax Pharmaceuticals	$10.36 -2.9%	$11.24	$8.58 ▼ $25.07	$891.02M	0.74	1.79 million shs	271,795 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-2.51%	+1.87%	+26.40%	+24.23%	+41.44%
ACLX Arcellx	+0.51%	+0.39%	+14.18%	-7.21%	+20.80%
MRUS Merus	+0.62%	-1.11%	+35.36%	+17.60%	-2.24%
SNDX Syndax Pharmaceuticals	-2.11%	-4.39%	+4.71%	-17.61%	-47.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.2643 of 5 stars	3.3	1.0	0.0	3.3	4.2	1.3
ACLX Arcellx	2.6574 of 5 stars	3.5	3.0	0.0	2.8	2.5	0.0
MRUS Merus	3.0924 of 5 stars	4.6	3.0	0.0	2.1	1.7	0.0
SNDX Syndax Pharmaceuticals	2.7884 of 5 stars	3.5	0.0	4.4	1.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	23.24% Upside
ACLX Arcellx	3.07	Buy	$111.33	67.82% Upside
MRUS Merus	3.13	Buy	$85.83	55.54% Upside
SNDX Syndax Pharmaceuticals	2.91	Moderate Buy	$35.91	246.58% Upside

Current Analyst Ratings Breakdown

Latest SNDX, MRUS, ACAD, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$26.00 ➝ $26.00
5/19/2025	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $28.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $30.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$996.28M	3.65	N/A	N/A	$2.63 per share	8.26
ACLX Arcellx	$76.81M	47.60	N/A	N/A	$9.97 per share	6.65
MRUS Merus	$54.73M	69.79	N/A	N/A	$6.17 per share	8.94
SNDX Syndax Pharmaceuticals	$43.72M	20.39	N/A	N/A	$6.53 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	27.86	28.60	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
ACLX Arcellx	-$70.69M	-$2.99	N/A	N/A	N/A	-25.94%	-8.28%	-5.21%	8/14/2025 (Estimated)
MRUS Merus	-$154.94M	-$4.08	N/A	N/A	N/A	-680.61%	-38.89%	-31.16%	7/30/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$209.36M	-$3.86	N/A	N/A	N/A	N/A	-64.34%	-57.72%	8/7/2025 (Estimated)

Latest SNDX, MRUS, ACAD, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
ACLX Arcellx	N/A	4.29	4.29
MRUS Merus	N/A	8.32	8.32
SNDX Syndax Pharmaceuticals	N/A	6.99	6.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ACLX Arcellx	96.03%
MRUS Merus	96.14%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ACLX Arcellx	8.35%
MRUS Merus	4.57%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
ACLX Arcellx	80	55.11 million	50.70 million	Optionable
MRUS Merus	37	69.21 million	65.34 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	81.86 million	Optionable

SNDX, MRUS, ACAD, and ACLX Headlines

Recent News About These Companies

Syndax reports publication of revumenib data from BEAT AML trial

June 13 at 11:25 AM | msn.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.

June 13 at 4:35 AM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?

June 12 at 2:47 PM | marketbeat.com

Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj

June 12 at 1:31 PM | thepharmaletter.com

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 12 at 12:02 PM | globenewswire.com

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 12 at 7:00 AM | globenewswire.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 7, 2025 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 5, 2025 | marketbeat.com

Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax

June 3, 2025 | biospace.com

Nuveen Asset Management LLC Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 1, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP

May 31, 2025 | marketbeat.com

Voloridge Investment Management LLC Takes $1.05 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 31, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.9% - Still a Buy?

May 30, 2025 | marketbeat.com

Syndax Announces Participation in June Investor Conferences

May 29, 2025 | globenewswire.com

Polar Asset Management Partners Inc. Invests $1.12 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 29, 2025 | marketbeat.com

Millennium Management LLC Has $7.76 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 28, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

May 28, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP

May 27, 2025 | marketbeat.com

Two Sigma Advisers LP Has $7.09 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX, MRUS, ACAD, and ACLX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.73 -0.01 (-0.03%)

As of 12:55 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx NASDAQ:ACLX

$66.34 -0.17 (-0.26%)

As of 12:54 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Merus NASDAQ:MRUS

$55.18 -0.21 (-0.37%)

As of 12:54 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Syndax Pharmaceuticals NASDAQ:SNDX

$10.36 -0.31 (-2.90%)

As of 12:55 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time